BR0308109A - Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila - Google Patents
Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arilaInfo
- Publication number
- BR0308109A BR0308109A BR0308109-5A BR0308109A BR0308109A BR 0308109 A BR0308109 A BR 0308109A BR 0308109 A BR0308109 A BR 0308109A BR 0308109 A BR0308109 A BR 0308109A
- Authority
- BR
- Brazil
- Prior art keywords
- atom
- group
- pyridinyl
- pyrimidinyl
- tetrahydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
Abstract
"DERIVADOS 2-PIRIDINIL E 2-PIRIMIDINIL-6,7,8,9-TETRAIDRO-PIRIMIDO[1,2-AIPIRIMIDIN-4 -ONA SUBSTITUìDOS COM HETERO ARILA". A presente invenção refere-se a um derivado de pirimidona representado pela fórmula (1) ou um seu sal onde: (1) X representa dois átomos de hidrogênio, um átomo de enxofre, um átomo de oxigênio ou um grupo alquila C~ 1-2~ e um átomo de hidrogênio; Y representa uma ligação, um grupo etenileno, um grupo etinileno, ou um grupo metileno opcionalmente substituído; R1 representa um anel 2, 3 ou 4-piridina ou um anel 2, 4 ou 5-pirimidina opcionalmente substituído; R2 representa um anel bicíclico heterocíclico, tendo 1-4 heteroátomos selecionados de um átomo de oxigênio, um átomo de enxofre e um átomo de nitrogênio e tendo 5-9 átomos de carbono, de fórmula (II) R3 representa um átomo de hidrogênio, um grupo alquila C~ 1-6~, um grupo hidróxi, um grupo alcóxi C~ 1-4~ ou um átomo de halogênio; R4 representa um átomo de hidrogênio, um grupo alquila C~ 1-6~ um grupo alcóxi C~ 1-4~ ou um átomo de halogênio. A invenção refere-se também a um medicamento compreendendo o dito derivado ou um seu sal como um ingrediente ativo que é usado para o tratamento preventivo e/ou terapêutico de uma doença neurodegenerativa causada por anormal atividade de GSK3<225> ou GSK3<225> e cdk5/p25, tal como mal de Alzheimer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02290486A EP1348708A1 (en) | 2002-02-28 | 2002-02-28 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
EP02290485A EP1340758A1 (en) | 2002-02-28 | 2002-02-28 | Heteroaryl substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
PCT/EP2003/002651 WO2003072579A1 (en) | 2002-02-28 | 2003-02-26 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308109A true BR0308109A (pt) | 2005-01-04 |
Family
ID=27767034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308109-5A BR0308109A (pt) | 2002-02-28 | 2003-02-26 | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila |
Country Status (22)
Country | Link |
---|---|
US (2) | US7232827B2 (pt) |
EP (1) | EP1480983B1 (pt) |
JP (1) | JP4458851B2 (pt) |
KR (1) | KR101030629B1 (pt) |
CN (1) | CN1315832C (pt) |
AR (1) | AR038619A1 (pt) |
AT (1) | ATE309247T1 (pt) |
AU (1) | AU2003221500B9 (pt) |
BR (1) | BR0308109A (pt) |
CA (1) | CA2474823C (pt) |
DE (1) | DE60302221T2 (pt) |
DK (1) | DK1480983T3 (pt) |
EA (1) | EA007737B1 (pt) |
ES (1) | ES2250883T3 (pt) |
IL (1) | IL163287A (pt) |
MX (1) | MXPA04008364A (pt) |
NO (1) | NO329805B1 (pt) |
NZ (1) | NZ534466A (pt) |
PL (1) | PL372465A1 (pt) |
SI (1) | SI1480983T1 (pt) |
TW (1) | TWI303637B (pt) |
WO (1) | WO2003072579A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1454910A1 (en) | 2003-03-07 | 2004-09-08 | Sanofi-Synthelabo | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
MXPA05009575A (es) | 2003-03-07 | 2006-05-19 | Sanofi Aventis | Derivados de 2-(diaza-biciclo-alquil)-pirimidona substituidos. |
EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
WO2005083105A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b) |
DE102004010194A1 (de) * | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
PT2448940E (pt) * | 2009-07-02 | 2014-09-03 | Sanofi Sa | Derivados de 6,7,8,9-tetra-hidro-pirimido{1,2-α} pirimidin- 4-ona, sua preparação e sua utilização farmacêutica |
JP5663571B2 (ja) * | 2009-07-02 | 2015-02-04 | サノフイ | 新規2,3−ジヒドロ−1H−イミダゾ{1,2−a}ピリミジン−5−オン誘導体、これらの調製およびこれらの薬学的使用 |
FR2947551B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
FR2947550B1 (fr) * | 2009-07-02 | 2012-05-18 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
CN102715186A (zh) * | 2012-06-15 | 2012-10-10 | 王学权 | 一种增效除草组合物 |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
BR112016022519A8 (pt) * | 2014-04-01 | 2018-03-06 | Pfizer | cromeno e 1,1a,2,7b-tetra-hidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gama-secretase |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
US11130762B2 (en) * | 2017-05-24 | 2021-09-28 | Abbisko Therapeutics Co., Ltd. | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
ES2222396T3 (es) * | 2000-09-01 | 2005-02-01 | Sanofi-Aventis | Compuestos utiles como ingrediente activo de un medicamento para el tratamiento preventivo y/o terapeutico de enfermedades neurodegenerativas. |
-
2003
- 2003-02-26 ES ES03717210T patent/ES2250883T3/es not_active Expired - Lifetime
- 2003-02-26 AT AT03717210T patent/ATE309247T1/de active
- 2003-02-26 AU AU2003221500A patent/AU2003221500B9/en not_active Ceased
- 2003-02-26 NZ NZ534466A patent/NZ534466A/en not_active IP Right Cessation
- 2003-02-26 BR BR0308109-5A patent/BR0308109A/pt active Search and Examination
- 2003-02-26 PL PL03372465A patent/PL372465A1/xx not_active IP Right Cessation
- 2003-02-26 CA CA2474823A patent/CA2474823C/en not_active Expired - Fee Related
- 2003-02-26 DE DE60302221T patent/DE60302221T2/de not_active Expired - Lifetime
- 2003-02-26 DK DK03717210T patent/DK1480983T3/da active
- 2003-02-26 CN CNB038092549A patent/CN1315832C/zh not_active Expired - Fee Related
- 2003-02-26 JP JP2003571285A patent/JP4458851B2/ja not_active Expired - Fee Related
- 2003-02-26 SI SI200330138T patent/SI1480983T1/sl unknown
- 2003-02-26 KR KR1020047013466A patent/KR101030629B1/ko not_active IP Right Cessation
- 2003-02-26 US US10/504,677 patent/US7232827B2/en not_active Expired - Fee Related
- 2003-02-26 WO PCT/EP2003/002651 patent/WO2003072579A1/en active IP Right Grant
- 2003-02-26 EP EP03717210A patent/EP1480983B1/en not_active Expired - Lifetime
- 2003-02-26 MX MXPA04008364A patent/MXPA04008364A/es active IP Right Grant
- 2003-02-26 EA EA200400936A patent/EA007737B1/ru not_active IP Right Cessation
- 2003-02-27 TW TW092104217A patent/TWI303637B/zh not_active IP Right Cessation
- 2003-02-28 AR ARP030100657A patent/AR038619A1/es unknown
-
2004
- 2004-07-29 IL IL163287A patent/IL163287A/en not_active IP Right Cessation
- 2004-08-26 NO NO20043565A patent/NO329805B1/no not_active IP Right Cessation
-
2007
- 2007-05-16 US US11/749,349 patent/US7465737B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0308109A (pt) | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
BR0212904A (pt) | Derivados substituìdos de 2-pirimidinil-6,7,8,9-tetraidropirimido-{1,2-a}pirimidin- 4-ona e 7-pirimidinil-2,3-diidroimidazo-{1,2-a}pirimi-din-5(1h)-on a para distúrbios neurodegenerativos | |
BRPI0408189A (pt) | 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas | |
BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
BR0212896A (pt) | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos | |
BRPI0417208A (pt) | derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona | |
BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
DE69922823D1 (de) | 6-SUBSTITUIERTE PYRAZOLO(3,4-d)PYRIMIDIN-4-ONE VERWENDBAR ALS CYCLIN-ABHÄNGIGE KINASEHEMMER | |
ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
BRPI0513750A (pt) | 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
DE60212836D1 (de) | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten | |
BR0312288A (pt) | Derivados de amidas | |
EA200970637A1 (ru) | 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы | |
ATE242246T1 (de) | (1,2,3)-triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel | |
ATE348101T1 (de) | Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion | |
MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
DE60221425D1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren | |
BR0308106A (pt) | Derivados de 1-[alquil], 1[(heteroaril)alquil] e 1-[(aril)alquil]-7-(pirimidin-4-il)-imidazo[1,2-a]pirimidin-5- (1h)-ona | |
ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
BR0010693A (pt) | Derivados azaindol para tratamento de depressão | |
PT1315730E (pt) | Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2246 DE 21/01/2014. |
|
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |